A First-in-human Phase 1 Dose Escalation Study of SAR428926 in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 19 Apr 2018
At a glance
- Drugs SAR 428926 (Primary)
- Indications Breast cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Sanofi
- 12 Apr 2018 Planned End Date changed from 2 Apr 2018 to 15 Jun 2018.
- 12 Apr 2018 Planned primary completion date changed from 2 Apr 2018 to 15 Jun 2018.
- 10 Jan 2018 Planned End Date changed from 20 Apr 2020 to 2 Apr 2018.